Comparing different day regimes of preoperative Conbercept administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a prospective randomized controlled clinical triaDat

Effect of different days of preoperative Conbercept administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a prospective randomized controlled clinical triaDat

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17014160

Enrollment

Unknown

Registered

2017-12-26

Start date

2017-06-01

Completion date

Unknown

Last updated

2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic retinopathy

Interventions

IVC-1d:Intravitreous injection of Conbercept 1 day before vitrectomy

IVC-3d:Intravitreous injection of Conbercept 3 days before vitrectomy

IVC-5d:Intravitreous injection of Conbercept 5 days before vitrectomy

IVC-7d:Intravitreous injection of Conbercept 7 days before vitrectomy

IVC-sham:Sham intravitreous injection of Conbercept 3 days before vitrectomy

non-PDR:patients with macular hole receiving vitrectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with proliferative diabetic retinopathy who need surgical treatment

Exclusion criteria

Exclusion criteria: 1. Not willing to participant; 2. Newly vitreous hemorrhage ( 9 mmol/L; 4. Eyes received previous PPV or anti-VEGF treatment; 5. Combined with systemic diseases which may potentially impact the cyctokines in serum, vitreous, or aqueous humor; 6. Stroke, thrombus, heart attach within 6 months; 7. Eyes with other conditions such as neovascular glaucoma, AMD, RVO or uveitis.

Design outcomes

Primary

Measure	Time frame
Vitreous VEGF;	—

Secondary

Measure	Time frame
Other cytokines in serum, vitreous, and aqueous humor;surgery time;intraoperative complications (hemorrhage or iatrogenic retinal breaks);postoperative hemorrhage;OCTA change;	—

Countries

China

Contacts

Public ContactQinghuai Liu

The first affiliated hospital of Nanjing Medical University

liuqh@njmu.edu.cn+86 13901585755

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026